DYNAMICS OF CHARACTERISTICS OF THE GLYCEMICAL PROFILE OF PATIENTS WITH CORONARY HEART DISEASE AND OBESITY AFTER TREATMENT

Introduction. Cardiovascular diseases (CVD) have the status of an epidemic, as they have high levels of prevalence and are the main cause of disability and mortality both in Ukraine and in the world and cause a significant increase in health care costs. Among all CVDs, coronary heart disease (CHD) ranks first. Many studies confirm a high percentage of CHD among all CVDs, especially in comorbidity with hyperlipidemia and obesity. Therefore, when treating CHD disease with obesity, it is necessary to take into account the effectiveness of the applied pharmacological agents and determine the dynamics of pharmacological intervention. The aim. To determine the dynamics of indicators of the glycemic profile in the comorbid course of CHD and obesity after the treatment. Materials and methods. It was conducted a randomized controlled single-center prospective study case-control, which is based on the analysis of the results of 130 people aged 25–85 were examined, who were divided into 3 groups: 70 persons (main group) with CHD on the background of obesity and 35 people with isolated coronary artery disease (comparison group) and control group (25 practically healthy people). The studied groups were randomized by age and gender. Results. Before treatment, a probable predominance of daily glucose levels was determined in patients main group to the patients comparison group and controls. According to the results of the glucose tolerance test (GTT), an improbable excess of fasting glucose levels and after a glucose load was determined in CHD with obesity (respectively 5.64±1.92 and 7.08±2.25 mmol/l) compared to the isolated of CHD (respectively 5, 15±2.22 (p=0.791) and 6.20±3.15 (p=0.403) mmol/l) and control group (respectively 5.32±0.49 (p=0.685) and 5.42±0, 51 (p<0.001) mmol/l). After treatment, recovery of blood glucose levels was determined. Conclusions. It was established that the characteristics of the dynamics of glucose metabolism indicators can be used as an indicator of the effectiveness of the treatment in the comorbidity of obesity and CHD. The obtained results indicate that the characteristics of glucose metabolism in the comorbidity of CHD and obesity must be taken into account to ensure therapeutic and preventive measures.